A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson

The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed by Pfizer, Moderna, and Johnson & Johnson....

Full description

Saved in:
Bibliographic Details
Published inHuman vaccines & immunotherapeutics Vol. 18; no. 1; p. 2002083
Main Authors Patel, Rikin, Kaki, Mohamad, Potluri, Venkat S., Kahar, Payal, Khanna, Deepesh
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 31.12.2022
Taylor & Francis Group
Subjects
coronavirus
Coronavirus – Review
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Johnson & Johnson
Moderna
Pandemics - prevention & control
Pfizer
Review
SARS-CoV-2
United States
Vaccination
Vaccine
United States
COVID-19
SARS-CoV-2
Johnson & Johnson
Pfizer
Moderna
coronavirus
Vaccine
Online AccessGet full text

Cover

Abstract The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed by Pfizer, Moderna, and Johnson & Johnson. Pfizer and Moderna developed mRNA vaccines, encoding the spike protein of SARS-CoV-2, whereas Johnson & Johnson developed an adenovirus vector-based vaccine. Safety has been shown in a large cohort of participants in clinical trials as well as the general population since emergency approval of vaccine administration in the US. Clinical trial results showed the Pfizer and Moderna vaccines to be 95.0%, and the Johnson & Johnson vaccine to be 66.0% effective in protecting against moderate and symptomatic SARS-CoV-2 infection. It is important to keep medical literature updated with the ongoing trials of these vaccinations, especially as they are tested among different age groups and upon the emergence of novel variants of the SARS-CoV-2 coronavirus.
AbstractList The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed by Pfizer, Moderna, and Johnson & Johnson. Pfizer and Moderna developed mRNA vaccines, encoding the spike protein of SARS-CoV-2, whereas Johnson & Johnson developed an adenovirus vector-based vaccine. Safety has been shown in a large cohort of participants in clinical trials as well as the general population since emergency approval of vaccine administration in the US. Clinical trial results showed the Pfizer and Moderna vaccines to be 95.0%, and the Johnson & Johnson vaccine to be 66.0% effective in protecting against moderate and symptomatic SARS-CoV-2 infection. It is important to keep medical literature updated with the ongoing trials of these vaccinations, especially as they are tested among different age groups and upon the emergence of novel variants of the SARS-CoV-2 coronavirus.
The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed by Pfizer, Moderna, and Johnson & Johnson. Pfizer and Moderna developed mRNA vaccines, encoding the spike protein of SARS-CoV-2, whereas Johnson & Johnson developed an adenovirus vector-based vaccine. Safety has been shown in a large cohort of participants in clinical trials as well as the general population since emergency approval of vaccine administration in the US. Clinical trial results showed the Pfizer and Moderna vaccines to be 95.0%, and the Johnson & Johnson vaccine to be 66.0% effective in protecting against moderate and symptomatic SARS-CoV-2 infection. It is important to keep medical literature updated with the ongoing trials of these vaccinations, especially as they are tested among different age groups and upon the emergence of novel variants of the SARS-CoV-2 coronavirus.The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed by Pfizer, Moderna, and Johnson & Johnson. Pfizer and Moderna developed mRNA vaccines, encoding the spike protein of SARS-CoV-2, whereas Johnson & Johnson developed an adenovirus vector-based vaccine. Safety has been shown in a large cohort of participants in clinical trials as well as the general population since emergency approval of vaccine administration in the US. Clinical trial results showed the Pfizer and Moderna vaccines to be 95.0%, and the Johnson & Johnson vaccine to be 66.0% effective in protecting against moderate and symptomatic SARS-CoV-2 infection. It is important to keep medical literature updated with the ongoing trials of these vaccinations, especially as they are tested among different age groups and upon the emergence of novel variants of the SARS-CoV-2 coronavirus.
Author Patel, Rikin
Potluri, Venkat S.
Kahar, Payal
Kaki, Mohamad
Khanna, Deepesh
Author_xml – sequence: 1
  givenname: Rikin
  surname: Patel
  fullname: Patel, Rikin
  organization: Nova Southeastern University
– sequence: 2
  givenname: Mohamad
  surname: Kaki
  fullname: Kaki, Mohamad
  organization: Nova Southeastern University
– sequence: 3
  givenname: Venkat S.
  surname: Potluri
  fullname: Potluri, Venkat S.
  organization: Nova Southeastern University
– sequence: 4
  givenname: Payal
  surname: Kahar
  fullname: Kahar, Payal
  organization: Marieb College of Health & Human Services, Florida Gulf Coast University
– sequence: 5
  givenname: Deepesh
  orcidid: 0000-0002-8673-8297
  surname: Khanna
  fullname: Khanna, Deepesh
  email: dkhanna@nova.edu
  organization: Nova Southeastern University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35130825$$D View this record in MEDLINE/PubMed
BookMark eNqFkktv1DAUhS1UREvpTwB5hViQ4kecOCAhRiMeRUWgFhA7y3GuO64Se7AzU5Vfj8PMFMoCvLCv7Hu-cyWf-2jPBw8IPaTkmBJJnjFalUJQccwIo3kjjEh-Bx1M94UQ5be9m5qKfXSU0iXJqyasrKp7aJ8Lyolk4gCdzbAJwzLCAnxya8AR1g6ucLD4fHZ2XszD14LhtTbGeUjP8SfrfkB8ij-EDqLX-DF-HxY-Bf-7eoDuWt0nONqeh-jLm9ef5--K049vT-az08JUhIyFbnXJzDRRa0ht82yW8c4aw2xDay0b03ANTR66JRK4BdJqLoBACUbWVckP0cmG2wV9qZbRDTpeq6Cd-nUR4oXScXSmB9XxmoFlJZQGypaRhkvTkA4o5ULUHDLr5Ya1XLUDdAb8GHV_C3r7xbuFughrJWXFqGgy4MkWEMP3FaRRDS4Z6HvtIaySYhWrZMO45Ln10Z9eNya7T8kNLzYNJoaUIlhl3KhHFyZr1ytK1JQCtUuBmlKgtinIavGXemfwP92rjc55G-Kgr0LsOzXq6z5EG7U3Lin-b8RPZBbGRA
CitedBy_id crossref_primary_10_1080_14760584_2022_2148660
crossref_primary_10_1158_2159_8290_CD_24_0158
crossref_primary_10_1265_ehpm_23_00061
crossref_primary_10_3390_microorganisms13030604
crossref_primary_10_36233_0372_9311_573
crossref_primary_10_3390_microorganisms10051021
crossref_primary_10_3390_vaccines12121419
crossref_primary_10_3390_ijms232315136
crossref_primary_10_3390_biom14101320
crossref_primary_10_7759_cureus_49204
crossref_primary_10_1016_j_dhjo_2023_101509
crossref_primary_10_1016_j_antiviral_2023_105590
crossref_primary_10_3389_fimmu_2022_864838
crossref_primary_10_7759_cureus_32437
crossref_primary_10_1016_j_isci_2024_110019
crossref_primary_10_1186_s12905_024_03349_9
crossref_primary_10_3389_fimmu_2024_1339660
crossref_primary_10_3389_fped_2022_883953
crossref_primary_10_1080_17460441_2023_2248879
crossref_primary_10_1097_MS9_0000000000001674
crossref_primary_10_3389_fimmu_2023_1284047
crossref_primary_10_3390_organoids3010002
crossref_primary_10_3390_v16040550
crossref_primary_10_1016_j_ijbiomac_2024_139395
crossref_primary_10_1002_iid3_946
crossref_primary_10_3390_vaccines12111220
crossref_primary_10_1016_j_pep_2025_106686
crossref_primary_10_1136_bmjopen_2024_086301
crossref_primary_10_3390_ijms24032957
crossref_primary_10_7759_cureus_55571
crossref_primary_10_1159_000543182
crossref_primary_10_3390_microorganisms11112618
crossref_primary_10_3390_vaccines13010030
crossref_primary_10_3390_life14020210
crossref_primary_10_1063_5_0125692
crossref_primary_10_1007_s10439_023_03305_y
crossref_primary_10_1007_s10529_024_03525_9
crossref_primary_10_2147_EB_S454977
crossref_primary_10_3390_v16020199
crossref_primary_10_1155_cjid_3804576
crossref_primary_10_3390_microorganisms11010191
crossref_primary_10_1080_03007995_2024_2303417
crossref_primary_10_1002_jmv_70133
crossref_primary_10_1007_s00277_024_05671_6
crossref_primary_10_1080_22221751_2023_2209208
crossref_primary_10_1093_infdis_jiad544
crossref_primary_10_3390_v16060973
crossref_primary_10_1093_hropen_hoac020
crossref_primary_10_12701_jyms_2025_42_23
crossref_primary_10_3390_vaccines10081237
crossref_primary_10_1177_15347346241275785
crossref_primary_10_3389_frdem_2023_1233340
crossref_primary_10_7759_cureus_33740
crossref_primary_10_3390_ijms232213911
crossref_primary_10_3390_vaccines13030327
crossref_primary_10_1021_acs_jproteome_2c00514
crossref_primary_10_3390_biomedicines11082203
crossref_primary_10_1016_j_rpth_2024_102419
crossref_primary_10_3389_fimmu_2023_1296603
crossref_primary_10_1002_prca_202300048
crossref_primary_10_1016_j_jconrel_2024_06_007
crossref_primary_10_1002_jmv_28776
crossref_primary_10_3390_vaccines11091408
crossref_primary_10_1016_j_bcp_2023_115688
crossref_primary_10_1016_j_pdpdt_2022_103015
crossref_primary_10_3390_vaccines12101172
crossref_primary_10_1016_j_cgh_2023_01_029
crossref_primary_10_1016_j_jmb_2023_168113
crossref_primary_10_3389_fimmu_2022_1035151
crossref_primary_10_3390_vaccines12010039
crossref_primary_10_3390_pathogens14010023
crossref_primary_10_1080_17460441_2022_2153828
crossref_primary_10_3389_fmed_2022_956158
crossref_primary_10_1016_j_dwt_2024_100283
crossref_primary_10_31857_S0132342323010232
crossref_primary_10_1016_j_heliyon_2024_e34927
crossref_primary_10_7759_cureus_66942
crossref_primary_10_1016_j_ejpn_2023_06_009
crossref_primary_10_1016_j_cis_2024_103156
crossref_primary_10_1021_acsmedchemlett_2c00231
crossref_primary_10_7759_cureus_28530
crossref_primary_10_1007_s12539_024_00643_w
crossref_primary_10_1002_wnan_1996
crossref_primary_10_1134_S1068162023010235
crossref_primary_10_19163_2307_9266_2023_11_3_193_210
crossref_primary_10_1007_s13181_023_00931_9
crossref_primary_10_1039_D3TB02895J
crossref_primary_10_5694_mja2_51750
crossref_primary_10_1016_j_vaccine_2023_10_008
crossref_primary_10_1136_bcr_2022_251361
crossref_primary_10_3390_biomedinformatics3010004
crossref_primary_10_3389_fmicb_2023_1117494
crossref_primary_10_3390_vaccines12030260
crossref_primary_10_1002_cpz1_898
crossref_primary_10_3390_vaccines11071232
crossref_primary_10_1016_j_eclinm_2024_102588
crossref_primary_10_3390_cancers14225537
crossref_primary_10_3390_microorganisms13010135
crossref_primary_10_3390_vaccines10111887
crossref_primary_10_1039_D3NA01097J
crossref_primary_10_3390_v15061366
crossref_primary_10_1002_btm2_10492
crossref_primary_10_3390_pharmaceutics17030379
crossref_primary_10_5005_jp_journals_10018_1405
crossref_primary_10_7759_cureus_42075
crossref_primary_10_1016_j_addr_2023_114965
crossref_primary_10_1016_j_imu_2024_101564
crossref_primary_10_7759_cureus_65192
crossref_primary_10_1021_acs_bioconjchem_3c00186
crossref_primary_10_7759_cureus_30555
crossref_primary_10_3390_v15091786
crossref_primary_10_3390_biom12060796
crossref_primary_10_3390_jpm14111092
crossref_primary_10_3390_nu14153215
crossref_primary_10_3389_fcimb_2024_1468775
crossref_primary_10_3390_vaccines10122070
crossref_primary_10_3390_nu15081807
crossref_primary_10_1007_s00417_022_05953_7
crossref_primary_10_7759_cureus_51076
crossref_primary_10_3390_ijms24108711
crossref_primary_10_12688_f1000research_140395_2
crossref_primary_10_12688_f1000research_140395_1
crossref_primary_10_5937_jomb0_47588
crossref_primary_10_7759_cureus_51501
crossref_primary_10_18231_j_ijcbr_2023_057
crossref_primary_10_1093_infdis_jiad193
crossref_primary_10_3390_v16040497
crossref_primary_10_1177_2632010X231161222
crossref_primary_10_3390_vaccines12050482
crossref_primary_10_1186_s12879_023_08261_5
crossref_primary_10_7759_cureus_45231
crossref_primary_10_1002_iid3_1323
crossref_primary_10_1002_hsr2_70119
crossref_primary_10_3390_vaccines10050709
Cites_doi 10.1056/NEJMoa2114255
10.1038/s41591-021-01583-4
10.7554/eLife.69091
10.1101/2021.05.09.443299
10.1016/S0140-6736(21)00947-8
10.1056/NEJMoa2022483
10.1101/2021.08.06.21261707
10.15585/mmwr.mm7009e4
10.1136/bmj.m3967
10.15585/mmwr.mm7032e4
10.1016/S1473-3099(21)00451-5
10.1007/s42399-021-00915-2
10.1186/s13584-021-00440-6
10.1056/NEJMc2102179
10.1056/NEJMoa2034577
10.1056/NEJMoa2101544
10.1016/j.compbiomed.2021.104210
10.2139/ssrrn.3909743
10.1101/2021.07.01.450707
10.21203/rs.3.rs-143532/v1
10.1101/2021.09.15.21263633
10.1056/NEJMoa2034201
10.1038/s41586-020-03098-3
10.3892/ijmm.2020.4596
10.1016/j.bja.2020.12.020
10.1056/NEJMoa2035389
ContentType Journal Article
Copyright 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022
2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
Copyright_xml – notice: 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022
– notice: 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
DBID 0YH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1080/21645515.2021.2002083
DatabaseName Taylor & Francis Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate R. PATEL ET AL
EISSN 2164-554X
ExternalDocumentID oai_doaj_org_article_d372ef24e4ce4b20938c90de1135573e
PMC8862159
35130825
10_1080_21645515_2021_2002083
2002083
Genre Review
Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: funding
GroupedDBID ---
00X
0YH
30N
4.4
53G
AALUX
ABEIZ
ABUPF
ACGFS
ADBBV
ADCVX
AECIN
AENEX
AGYJP
AIJEM
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
ARJSQ
BABNJ
BAWUL
BLEHA
BOHLJ
CCCUG
DGEBU
DIK
EBS
EMOBN
GROUPED_DOAJ
H13
HYE
KYCEM
LJTGL
M4Z
O9-
RIG
RPM
SV3
TDBHL
TFL
TFW
TTHFI
AAYXX
CITATION
ACENM
AEXWM
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c600t-aba42c0246bc07f702f23dfcc2f917a89c93ae9070b08e3fe0ba35e0e4ec87643
IEDL.DBID 0YH
ISSN 2164-5515
2164-554X
IngestDate Wed Aug 27 01:32:01 EDT 2025
Thu Aug 21 18:13:51 EDT 2025
Fri Jul 11 00:21:10 EDT 2025
Thu Jan 02 22:55:18 EST 2025
Tue Jul 01 05:11:39 EDT 2025
Thu Apr 24 22:54:09 EDT 2025
Tue Apr 08 04:10:26 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
SARS-CoV-2
Johnson & Johnson
Pfizer
Moderna
coronavirus
Vaccine
Language English
License open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c600t-aba42c0246bc07f702f23dfcc2f917a89c93ae9070b08e3fe0ba35e0e4ec87643
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-8673-8297
OpenAccessLink https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.2002083
PMID 35130825
PQID 2626892383
PQPubID 23479
ParticipantIDs crossref_citationtrail_10_1080_21645515_2021_2002083
proquest_miscellaneous_2626892383
crossref_primary_10_1080_21645515_2021_2002083
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8862159
pubmed_primary_35130825
doaj_primary_oai_doaj_org_article_d372ef24e4ce4b20938c90de1135573e
informaworld_taylorfrancis_310_1080_21645515_2021_2002083
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-12-31
PublicationDateYYYYMMDD 2022-12-31
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-31
  day: 31
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Human vaccines & immunotherapeutics
PublicationTitleAlternate Hum Vaccin Immunother
PublicationYear 2022
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_8_49_1
e_1_3_8_28_1
e_1_3_8_47_1
e_1_3_8_26_1
e_1_3_8_22_1
e_1_3_8_45_1
e_1_3_8_24_1
e_1_3_8_43_1
e_1_3_8_41_1
e_1_3_8_20_1
e_1_3_8_18_1
e_1_3_8_39_1
e_1_3_8_16_1
e_1_3_8_37_1
e_1_3_8_8_1
e_1_3_8_6_1
e_1_3_8_4_1
e_1_3_8_2_1
e_1_3_8_10_1
e_1_3_8_35_1
e_1_3_8_12_1
e_1_3_8_33_1
e_1_3_8_31_1
e_1_3_8_52_1
e_1_3_8_50_1
e_1_3_8_29_1
e_1_3_8_27_1
e_1_3_8_25_1
e_1_3_8_48_1
FDA (e_1_3_8_11_1) 2021
Pardi NH (e_1_3_8_14_1) 2018; 6
e_1_3_8_21_1
e_1_3_8_46_1
e_1_3_8_23_1
e_1_3_8_44_1
e_1_3_8_42_1
e_1_3_8_40_1
e_1_3_8_19_1
e_1_3_8_15_1
e_1_3_8_38_1
e_1_3_8_17_1
e_1_3_8_36_1
e_1_3_8_9_1
e_1_3_8_7_1
e_1_3_8_5_1
e_1_3_8_3_1
e_1_3_8_34_1
e_1_3_8_13_1
e_1_3_8_32_1
e_1_3_8_30_1
e_1_3_8_53_1
e_1_3_8_51_1
References_xml – ident: e_1_3_8_21_1
  doi: 10.1056/NEJMoa2114255
– ident: e_1_3_8_25_1
  doi: 10.1038/s41591-021-01583-4
– ident: e_1_3_8_17_1
  doi: 10.7554/eLife.69091
– ident: e_1_3_8_34_1
  doi: 10.1101/2021.05.09.443299
– ident: e_1_3_8_52_1
– ident: e_1_3_8_44_1
– volume-title: Pfizer-BioNTech COVID-19 vaccine EUA Amendment Review Memorandum. fda.gov
  year: 2021
  ident: e_1_3_8_11_1
– ident: e_1_3_8_12_1
– ident: e_1_3_8_19_1
  doi: 10.1016/S0140-6736(21)00947-8
– ident: e_1_3_8_30_1
– ident: e_1_3_8_13_1
  doi: 10.1056/NEJMoa2022483
– ident: e_1_3_8_8_1
– ident: e_1_3_8_35_1
  doi: 10.1101/2021.08.06.21261707
– ident: e_1_3_8_49_1
  doi: 10.15585/mmwr.mm7009e4
– ident: e_1_3_8_50_1
  doi: 10.1136/bmj.m3967
– ident: e_1_3_8_2_1
– ident: e_1_3_8_51_1
  doi: 10.15585/mmwr.mm7032e4
– ident: e_1_3_8_53_1
– ident: e_1_3_8_6_1
– ident: e_1_3_8_29_1
  doi: 10.1016/S1473-3099(21)00451-5
– ident: e_1_3_8_3_1
  doi: 10.1007/s42399-021-00915-2
– ident: e_1_3_8_20_1
  doi: 10.1186/s13584-021-00440-6
– ident: e_1_3_8_33_1
  doi: 10.1056/NEJMc2102179
– ident: e_1_3_8_15_1
  doi: 10.1056/NEJMoa2034577
– ident: e_1_3_8_45_1
  doi: 10.1056/NEJMoa2101544
– ident: e_1_3_8_16_1
– ident: e_1_3_8_40_1
– ident: e_1_3_8_38_1
– ident: e_1_3_8_24_1
  doi: 10.1038/s41591-021-01583-4
– ident: e_1_3_8_10_1
– ident: e_1_3_8_46_1
– ident: e_1_3_8_4_1
  doi: 10.1016/j.compbiomed.2021.104210
– ident: e_1_3_8_41_1
– ident: e_1_3_8_26_1
  doi: 10.2139/ssrrn.3909743
– ident: e_1_3_8_48_1
  doi: 10.1101/2021.07.01.450707
– ident: e_1_3_8_18_1
  doi: 10.21203/rs.3.rs-143532/v1
– ident: e_1_3_8_22_1
  doi: 10.1101/2021.09.15.21263633
– ident: e_1_3_8_23_1
– ident: e_1_3_8_43_1
  doi: 10.1056/NEJMoa2034201
– ident: e_1_3_8_37_1
– ident: e_1_3_8_5_1
– ident: e_1_3_8_42_1
– ident: e_1_3_8_9_1
  doi: 10.1038/s41586-020-03098-3
– volume: 6
  start-page: 17
  year: 2018
  ident: e_1_3_8_14_1
  article-title: Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses
  publication-title: J Exp Med
– ident: e_1_3_8_31_1
– ident: e_1_3_8_28_1
– ident: e_1_3_8_36_1
– ident: e_1_3_8_39_1
– ident: e_1_3_8_47_1
– ident: e_1_3_8_7_1
  doi: 10.3892/ijmm.2020.4596
– ident: e_1_3_8_27_1
  doi: 10.1016/j.bja.2020.12.020
– ident: e_1_3_8_32_1
  doi: 10.1056/NEJMoa2035389
SSID ssj0000702466
Score 2.6077957
SecondaryResourceType review_article
Snippet The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2002083
SubjectTerms coronavirus
Coronavirus – Review
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Johnson & Johnson
Moderna
Pandemics - prevention & control
Pfizer
Review
SARS-CoV-2
United States
Vaccination
Vaccine
SummonAdditionalLinks – databaseName: DOAJ (Directory of Open Access Journals)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1baxQxFA5SEHwR7643IvhobCaXufi2FksRLGKt9C0kmRNakFnZboX213tOMrPsFmFffBrIJDA5Ocn5vknyHcbeVT5ZwEgnpAkgjPFBdL62og4WwYGqG0h0d_jrcX10ar6c2bONVF90JqzIAxfD7fe6UZCUARPBBIUEvI2d7KGqMFI2Gmj1xZi3QabyGtxg7MkblQr5gEBYYKfrO63cpzIqQnqoMkdUstVbgSnr999SL_0XBr19lHIjNh0-YPdHUMnnpTMP2R0YHrG7Jc3k9WN2POd0cnwJ5-W0Oi_3Vfgi8ZP59xNxsPgpFP_jI22yX37k39LFDSzf85InzfMxi9b0fMJODz__ODgSYx4FERHOrIQP3qhIBglRNglNk5TuU4wqIVnzbRc77QFZsgyyBZ1ABq8tSDAQcbE0-inbGxYDPGccSL_PVn0tweLA4uSvQ0-b91VE6GDaGTOTEV0cRcYp18UvV41apJPtHdnejbafsQ_rZr-LysauBp9ohNaVSSQ7F6DruNF13C7XmbFuc3zdKv8jSSWhidM7PuDt5AwOJyTtsvgBFleXTiFFbBE2U51nxTnWn6ltRfJAdsaaLbfZ6sf2m-HiPIt-t0g9EXq--B8df8nuKbrFkfUqX7G91fIKXiO2WoU3eRr9BeRvF1s
  priority: 102
  providerName: Directory of Open Access Journals
Title A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
URI https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.2002083
https://www.ncbi.nlm.nih.gov/pubmed/35130825
https://www.proquest.com/docview/2626892383
https://pubmed.ncbi.nlm.nih.gov/PMC8862159
https://doaj.org/article/d372ef24e4ce4b20938c90de1135573e
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEA96Ivgifrt-HBHEJ6NpPvrh23p4LIIid57oU0jSiXcgrezuCfrXO9O06-2h3INvpW1KOplkfpPM_Iaxp4VPFtDSCWkCCGN8EI0vrSiDRXCgygoS5Q6_e18ujszbz3aKJlyNYZXkQ6dMFDGs1TS5fVhNEXEvFUJ8NPQWvTs1uHgKccRldgUtsaQiBvLLYrPNghqt8okltRLUbMrj-deXtizUQOR_jsb0b2D0fEzlGSO1f4NdH9Eln2d1uMkuQXeLXc31Jn_eZgdzTiHkSzjOYes8J67wPvHD-cGh2Os_CcV_-Ein7atX_EM6-QXL5zwXTPP8GR8Lav25usOO9t983FuIsaiCiIht1sIHb1QkoYQoq4TiSUq3KUaV0HPzdRMb7QFdZhlkDTqBDF5bkGAg4spp9F220_Ud3GcciMzPFm0pweIo40pQhpZO8ouIOMLUM2YmQbo4Mo5T4YtvrhiJSSf5O5K_G-U_Yy82zb5nyo2LGrymUdq8TIzZw41--dWNE9C1ulKQlAETwQQlG13HRrZQFIi4Kg0z1pwdY7ceNkxSrm7i9AUdeDIphMPZSUcuvoP-dOUU-os1Ymh6515WkE03tS2IK8jOWLWlOlv_sf2kOzkeGMBr9EMRhz74jz4_ZNcUZXIMnJWP2M56eQqPEV-tw-4wg3aH3YnfLBEV1w
linkProvider Taylor & Francis
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1JbxMxFLZKEaIXdkpYjQScmODxMgsSh1CoUtpGqAvqzdjOM61ACcoCan8Wf4U_xPN4JjQRqAfUA7coGUdvxm_7PO99j5AnqfEKMNIlTFpIpDQ2KU2mkswqTA54loMPvcPbvay7L98dqIMl8qPphQlllQFD-0gUUfnqYNzhMLopiXvBMcfHSK8Q3vEK43FMJOrCyk04_o6wbfxq4w3u8VPO19_urXWTerJA4jDATxJjjeQOw1NmHct9zrjnou-d4x7hiylKVwoDiBuZZQUID8waoYCBBIfuQwr83wvkoiqzPNiWYL3ZuQ6u4fEVaZAyCWI2jUN_k3wuJFaTAxZ4U_-U_S4WcZ6KiutXyc_mecZimM_t6cS23ckC1eT_9cCvkSt1kk470aqukyUY3CCX4tjO45tkp0NDJf4IDmP1P439P3To6W5nZzdZG35IOP1mXChaGL-k7_3RCYye0zh3ztBntJ5L9vvTLbJ_Ljd0mywPhgO4QygETkSV9jMGCo0FHWpm-6EgInWYjsmiRWSjHtrVxO1hfsgXndb8rs326LA9ut6eFmnPln2NzCVnLXgddG92cSAer74Yjj7p2o_pvsg5eC5BOpCWs1IUrmR9SFNMXHMBLVKe1lw9qc6dfBwSo8UZAjxu1FyjkwtvrswAhtOx5gi7C4Qi4ZrVqPYzMYVKA-WSapF8ziDm7mP-l8HRYUWkXiCcx3T-7j_I_Ihc7u5tb-mtjd7mPbLCQ3NMRQN6nyxPRlN4gCnrxD6sfAQlH8_bRn4BfKGTnQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKEagX3pTlaSTgRBbHcV5IHJaWVUthVbUU9WZsZ0wrUFLtZkHtv-Kv8IsYx8nSXYF6QD1wW2XjaBLP60tmviHkSahsDBjpAiY0BEIoHeQqiYNEx5gc8CQF63qH34-SjT3xdj_eXyI_ul4YV1bpMLT1RBGNr3bGfVTYriLuBccUHwN9jOiONxCPYx7R1lVuwfF3RG2TV5vruMVPOR---bC2EbSDBQKD8b0OlFaCG4xOiTYstSnjlkeFNYZbRC8qy00eKUDYyDTLILLAtIpiYCDAoPcQEV73ArmYuMZO1zXCRrPXOriG-y-kTsrAidn1Df1N8rmI2AwOWKBN_VPyu1jDeSooDq-Sn93j9LUwX_rTWvfNyQLT5H_1vK-RK22KTgfepq6TJShvkEt-aOfxTbIzoK4OfwwHvvaf-u4fWlm6O9jZDdaqjwGn35RxJQuTl3TbHp7A-Dn1U-cUfUbbqWS_f90ie-dyQ7fJclmVcIdQcIyIcVgkDGI0FXSniS5cOURoMBkTWY-ITjukaWnb3fSQrzJs2V277ZFue2S7PT3Sny078rwlZy147VRvdrKjHW8OVOPPsvVisohSDpYLEAaE5iyPMpOzAsIQ09Y0gh7JTyuurJu3TtaPiJHRGQI87rRcootz361UCdV0IjmC7gyBiDtn1Wv9TMwoDh3hUtwj6Zw9zN3H_D_l4UFDo54hmMdk_u4_yPyIXN5eH8p3m6Ote2SFu86YhgP0Plmux1N4gPlqrR82HoKST-dtIr8A1IeSQQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+comprehensive+review+of+SARS-CoV-2+vaccines%3A+Pfizer%2C+Moderna+%26+Johnson+%26+Johnson&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Patel%2C+Rikin&rft.au=Kaki%2C+Mohamad&rft.au=Potluri%2C+Venkat+S.&rft.au=Kahar%2C+Payal&rft.date=2022-12-31&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=18&rft.issue=1&rft_id=info:doi/10.1080%2F21645515.2021.2002083&rft.externalDBID=n%2Fa&rft.externalDocID=10_1080_21645515_2021_2002083
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon